GEN Exclusives

More »

GEN Poll

Jun 15, 2009

Making Cancer Treatments Patient-Specific

Given the success of Dendreon’s and Biovest’s cancer vaccines in late-stage trials, some believe that the promise of personalized therapy in cancer is around the corner. Yet we’re also seeing other similar vaccines fail in Phase III studies. Manufacturing issues and the high cost of producing such therapies are some of the barriers that have been holding the field back. What’s your prediction for the future of personalized cancer medicine in the U.S.?

How long do you think it will take for a cancer vaccine to reach the U.S. market?

Within the next year or so
At least another five years

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »